Lipid nanoparticles (LNPs) have emerged as powerful delivery vehicles for a broad spectrum of therapeutic cargos, holding great promise for the treatment of numerous diseases. Nevertheless, a critical bottleneck in their broader application remains their inherent tropism toward the liver, driven by the natural lipid composition of the particles, which severely restricts targeted delivery to other tissues and organs. To address this challenge, our laboratory has engineered targeted LNPs through the site-specific conjugation of antibody fragments (Fab’) or nanobodies onto the LNP surface, conferring the ability to selectively home to distinct organs of interest.
